With the remarkable drop in tobacco use across the world, also dropped mortality associated to abdominal aorta aneurysm rupture (AAA). All AAA screening programs have been designed decades ago, when the risk was higher. This is why we might need to rethink these programs, or at least design new randomized controlled studies to pave the<a href="https://solaci.org/en/2018/06/22/are-abdominal-aortic-aneurysm-screening-programs-overstated/" title="Read more" >...</a>
The association between aortic stenosis and some degree of mitral stenosis (MS) is around 10% (depending on the series), and it is related with negative outcomes. In high-risk and inoperable patients who underwent TAVR, that association and its significance have not been studied yet. The study analyzed data from the Society of Thoracic Surgeons/American<a href="https://solaci.org/en/2018/04/21/we-should-consider-mitral-stenosis-before-tavr/" title="Read more" >...</a>
Pure aortic regurgitation has historically been considered a contraindication for transcatheter aortic valve replacement (TAVR) due to the absence of calcification and subsequent device anchoring problems it poses. Initial reports on first-generation self-expanding valves for the treatment of pure regurgitation were somewhat discouraging, but devices evolved, adding repositioning capacity, different external skirts (pericardial, PET, urethane,<a href="https://solaci.org/en/2017/12/26/tavr-in-pure-aortic-regurgitation-new-devices-new-outcomes/" title="Read more" >...</a>
Transcatheter aortic valve replacement (TAVR) is much less invasive than surgical replacement. This is associated with a substantial reduction in bleeding events (up to 60% less). However, clinically relevant bleeding is still present in one every four patients who undergo TAVR, which is associated with morbidity and mortality. Cases of bleeding are not uniform: they may<a href="https://solaci.org/en/2017/08/22/bleeding-and-mortality-in-transcatheter-aortic-valve-replacement/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. The balloon aortic valvuloplasty (BAV) was introduced by Dr. Cribier in 1986. However, given its poor results, soon after it fell into disuse. With the introduction of TAVR, it saw a revival as bridge for another intervention, even though it is still resisted in many places. The present study<a href="https://solaci.org/en/2017/06/07/in-hospital-morbid-mortality-rates-for-balloon-aortic-valvuloplasty-are-similar-to-those-for-transcatheter-aortic-valve-implantation/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Transcatheter aortic valve replacement (TAVR) has proven to be beneficial for extreme- and high-risk patients. It is also increasingly used in intermediate-risk patients, and it has been hinted at for low-risk patients. However, different sectors in the medical community still challenge the existence of real TAVR benefit. This assessment consisted<a href="https://solaci.org/en/2017/05/03/tavr-in-intermediate-risk-patients-is-it-as-effective-as-surgical-aortic-valve-replacement/" title="Read more" >...</a>
Courtesy of Dr. Agustín Vecchia. Surgery is the treatment of choice for patients with symptomatic aortic insufficiency and/or ventricular dilatation or decreased ventricular function. The broad implementation of transcatheter aortic valve replacement (TAVR) in patients with aortic stenosis, the emergence of new devices, and the experience acquired by operators have brought this treatment to off-label indications such<a href="https://solaci.org/en/2016/12/13/tavr-in-pure-aortic-insufficiency-yes-or-no/" title="Read more" >...</a>
Original Title: Aortic Regurgitation Following Transcatheter Aortic Valve Replacement: Impact of Preprocedural Left Ventricular Diastolic Filling Patterns on Late Clinical Outcomes. Reference: Amir Halkin, et al. Catheterization Cardiovascular Intervention 2016;87:1156-1163. Courtesy of Dr. Carlos Fava. Even though the mechanisms underlying post TAVI aortic regurgitation (ARpost) remain unclear, there is no question this complication is<a href="https://solaci.org/en/2016/06/01/bad-prognosis-in-patients-with-aortic-regurgitation-post-tavi/" title="Read more" >...</a>
Original Title: Outcomes in Patients with Transcatheter Aortic Valve Replacement and Left Main Stenting. The TAVR-LM Registry. Reference: TarunChakravarty et al. Journal of the American College of Cardiology, Vol 67, N° 8, 2016. Courtesy of Dr. Santiago F. Coroleu. High surgical risk patients with severe aortic stenosis and significant left main aortic arterydiseaseare often treated combining<a href="https://solaci.org/en/2016/03/22/tavr-lm-registry-transcatheter-aortic-valve-replacement-and-left-main-stenting/" title="Read more" >...</a>
Original Title: Regression of Paravalvular Aortic Regurgitation and Remodeling of Self-Expanding Transcatheter Aortic Valve. An Observation From the CoreValve U.S. Pivotal Trial. Reference: Jae K. Oh et al. J Am Coll Cardiol Img. 2015, online first. The aim of this study was to describe the natural evolution and the clinical significance of paravalvular aortic insufficiency after<a href="https://solaci.org/en/2015/11/20/spontaneous-regression-of-paravalvular-aortic-regurgitation-with-self-expanding-prosthesis/" title="Read more" >...</a>